Sagimet Biosciences (SGMT) Free Cash Flow (2022 - 2026)

Sagimet Biosciences' Free Cash Flow history runs 5 years deep, the most recent figure standing at -$8.6 million for Q1 2026.

• In Q1 2026, Free Cash Flow rose 40.76% year-over-year to -$8.6 million; the TTM figure through Mar 2026 stood at -$39.7 million (up 21.74% YoY), while the FY2025 annual figure was -$45.6 million, down 7.58% from the prior year.
• Free Cash Flow was -$8.6 million for Q1 2026 at Sagimet Biosciences, up from -$11.8 million in the prior quarter.
• In the past five years, Free Cash Flow ranged from a high of -$3000.0 in Q2 2022 to a low of -$19.6 million in Q3 2024.
• Historically, Free Cash Flow has averaged -$8.4 million across 5 years, with a median of -$7.3 million in 2022.
• The sharpest annual moves came in 2023 and 2025: Free Cash Flow slumped 190566.67% in 2023, then surged 47.98% in 2025.
• A 5-year view of Free Cash Flow shows it stood at -$7.5 million in 2022, then grew by 5.43% to -$7.1 million in 2023, then tumbled by 55.64% to -$11.0 million in 2024, then retreated by 7.34% to -$11.8 million in 2025, then gained by 27.23% to -$8.6 million in 2026.
• The last three Free Cash Flow figures came in at -$8.6 million (Q1 2026), -$11.8 million (Q4 2025), and -$10.2 million (Q3 2025), per Business Quant data.